Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The trial is testing epcoritamab, a biological treatment administered subcutaneously, either as a monotherapy or in combination with standard-of-care (SOC) chemotherapy agents. The goal is to ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a first-in-human study titled ...

The intervention involves the investigational drug ABBV-453, a BCL-2 inhibitor, administered orally. It is tested alone or in combination with daratumumab, dexamethasone, and pomalidomide, aiming to ...

North Chicago, Illinois-based AbbVie Inc. has shown a robust performance despite market fluctuations. While the broader ...

NYSE:ABBV 1 Year Share Price vs Fair Value Explore AbbVie's Fair Values from the Community and select yours ...

Despite AbbVie’s underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a moderately ...

AbbVie Inc reported a robust second quarter for 2025, with adjusted earnings per share of $2.97 and net revenues reaching $15 ...

As for its neuroscience portfolio, AbbVie has added $300 million, putting its projection for the year at $10.5 billion, which ...

After 24 weeks of treatment, Rinvoq at two doses—15 mg and 30 mg—helped 44.6% and 54.3% of adult alopecia patients achieve 80 ...

AbbVie has reportedly added Gilgamesh Pharmaceuticals to its shopping list. | AbbVie has reportedly added Gilgamesh ...

AbbVie said on Thursday its tariff exposure is not expected to exceed that of rivals, and raised its 2025 profit forecast ...